

Vedanta Medical Research Foundation (VMRF) Launches World-Class Oncology Facility, Balco Medical Centre, in Raipur

Balco Medical Centre is a flagship philanthropic initiative of the Vedanta Group with the noble aim of contributing towards prevention, control and eradication of cancer

Raipur, March 26, 2018: Dr. Raman Singh, Hon'ble Chief Minister of Chhattisgarh, inaugurated Central India's first world-class cancer facility BALCO Medical Centre (BMC) in Naya Raipur, today. BMC offers ultra-modern, multi-modality diagnostic and therapeutic cancer treatment. BALCO Medical Centre is an initiative of Vedanta Medical Research Foundation (VMRF), a non-profit initiative of Vedanta Resources and Bharat Aluminium Co Ltd (BALCO).

The facility has a mission to provide affordable, world-class cancer care to all. The Chief Minister lauded the entire BMC team on delivering a world-class cancer facility. The 170-bed tertiary care facility will deliver global standard cancer treatment, primarily serving the populations of Chhattisgarh and Central India.

Navin Agarwal, Chairman, Vedanta Ltd, said, "Giving back to the society is a key focus area for us, and the conceptualization of BALCO Medical Centre was through the identification of the lack of cancer care access in Central India. While this is a great occasion, our greater joy will be from tomorrow as we provide affordable world-class cancer treatment to the citizens of Chhattisgarh and Central India."

Speaking about the inauguration, **Anil Agarwal, Chairman, Vedanta Group** expressed his joy on the launch of this cancer care facility and the alignment of the initiative with the larger vision of Vedanta Group's commitment to give back to society. Further, he highlighted the fact that BMC is only the first step, and he looks forward to many more research & development initiatives from VMRF, going forward.

More than 2.5 million Indians live with cancer, and the disease sees more than 550,000 deaths every year. Research suggests 39.6% of Indians will be diagnosed with cancer during their lifetime, and 71% of all deaths occurring between the age groups of 30 to 69 years of age can be attributed to this disease. India accounts for the third highest cancer cases amongst women only after China and the US. Chhattisgarh, alone, is estimated to see 41,000 new cases of cancer by 2021. BALCO Medical Centre was conceptualized to address this alarming issue.

The hospital has been developed with key inputs and advisory from Tata Medical Centre, Kolkata and will look to provide the highest level of patient care in medical, surgical and radiation oncology. Commenting on the launch of the new facility, Dr Mammen Chandy, Director, Tata Medical Centre (Kolkata), observed, "It was great collaborating with the VMRF team and share learnings to create a world class facility. I am sure this is one of the top cancer care facilities in the country, and we are proud to be associated with this hospital."

Adding on, **Jyoti Agarwal, Chairperson, Vedanta Medical Research Foundation,** said, "The BALCO Medical Centre journey has been one that we have cherished, but we know we still have a larger purpose to achieve. Apart from providing the best cancer treatment, we will also develop an India-centric research centre for cancer and its treatment, training and development of the best oncology professionals. "



The hospital is equipped with state of the art infrastructure, diagnostic and treatment facilities, which will be the only integrated oncology hospital in the state of Chhattisgarh. Further, the hospital has been developed with key inputs and advisory from Tata Medical Centre, Kolkata and will look to provide the highest level of patient care in medical, surgical and radiation oncology. Along with this initiative, BMC will propagate cancer awareness and education in the entire region, while ensuring no individual goes without access to treatment.

About Vedanta Limited

Vedanta Limited is a diversified natural resources company, whose business primarily involves producing oil & gas, zinc - lead - silver, copper, iron ore, aluminium and commercial power. The company has a presence across India, South Africa, Namibia, Australia and Ireland. Vedanta Limited is the Indian subsidiary of Vedanta Resources Plc, a London-listed company.

Governance and Sustainable Development are at the core of Vedanta's strategy, with a strong focus on health, safety and environment and on enhancing the lives of local communities. The company is conferred with the Confederation of Indian Industry (CII) 'Sustainable Plus Platinum label', ranking among the top 10 most sustainable companies in India. To access the Vedanta Sustainable Development Report 2017, please visit <u>http://sd.vedantaresources.com/SustainableDevelopment2016-17/</u> Vedanta Limited is listed on the Bombay Stock Exchange and the National Stock Exchange in India and has ADRs listed on the New York Stock Exchange.

For more information please visit www.vedantalimited.com

Vedanta Limited Vedanta, 75, Nehru Road, Vile Parle (East), Mumbai - 400 099 www.vedantalimited.com

Registered Office:

Regd. Office: 1st Floor, 'C' wing, Unit 103, Corporate Avenue, Atul Projects, Chakala, Andheri (East), Mumbai – 400 093 CIN: L13209MH1965PLC291394

Disclaimer

This press release contains "forward-looking statements" – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "should" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, uncertainties arise from the behaviour of financial and metals markets including the London Metal Exchange, fluctuations in interest and or exchange rates and metal prices; from future integration of acquired businesses; and from numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive or regulatory nature. These uncertainties may cause our actual future results to be materially different that those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.